
CTVA · NYSE
Consensus is Buy across 23 analysts, with a mean target of $95; the supplied data give no low or high target, so target clustering and dispersion cannot be measured. No named analyst or brokerage is identified as most or least bullish, and no target or rating revisions during the week are supplied. The substantive evidence-based disagreement is operational rather than target-specific: Corteva raised its 2026 outlook and beat second-quarter EPS estimates, while sales fell 1% and profit declined as reduced seed volumes and competitive crop-protection pricing weighed. The dataset does not identify how analysts translate those opposing signals into targets.